四环医药(00460.HK) 公布,旗下非全资附属公司惠升生物与渼颜空间就惠升生物研发的用于超重或肥胖适应症的司美格鲁肽注射液达成独家授权合作。
惠升生物研发的司美格鲁肽是一种长效GLP-1受体激动剂,通过启动GLP-1受体,增强胰岛素分泌,抑制胰高血糖素分泌,延缓胃排空,增加饱腹感,减少食欲和进食量。该产品在中国大陆地区减重适应症已获批临床,2型糖尿病适应症已完成III期临床入组。(ha/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-21 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.